Filter Results

Locations

Study status

(for at least one location)

Gender

Age

Healthy Volunteer

What is this?
A volunteer subject with no known significant health problems who participates in research to test a new drug, device or intervention. These volunteers are recruited to serve as controls for patient groups. Healthy volunteers receive the same test, procedure, or drug the patient group receives.

Study phase

What is this?
During the early phases (phases 1 and 2), researchers assess safety, side effects, optimal dosages and risks/benefits. In the later phase (phase 3), researchers study whether the treatment works better than the current standard therapy. They also compare the safety of the new treatment with that of current treatments. Phase 3 trials include large numbers of people to make sure that the result is valid. There are also less common very early (phase 0) and later (phase 4) phases. Phase 0 trials are small trials that help researchers decide if a new agent should be tested in a phase 1 trial. Phase 4 trials look at long-term safety and effectiveness, after a new treatment has been approved and is on the market.

Search Results 121-130 of 628 for

  • Results filtered:
  • Study status: Open/Status Unknown
Edit search filters
  1. A Study to Evaluate Lenalidomide and Dexamethasone, with or without Daratumumab, in Treating High-Risk Smoldering Myeloma Patients

    Albert Lea, MN, Eau Claire, WI, Rochester, MN

  2. Testing the Addition of an Anti-cancer Drug, Selinexor, to the Usual Chemotherapy Treatment (Temozolomide) for Brain Tumors That Have Returned After Previous Treatment

    Scottsdale/Phoenix, AZ, Jacksonville, FL, Rochester, MN

  3. Indigenous Peoples Engagement in Cancer Research Arizona

    Scottsdale/Phoenix, AZ

  4. A Study of AZD2936 Anti-TIGIT/Anti-PD-1 Bispecific Antibody in Participants With Advanced or Metastatic NSCLC

    Rochester, MN

  5. A Study of 177Lu-FAP-2286 in Advanced Solid Tumors (LuMIERE)

    Rochester, MN, Jacksonville, FL

  6. MC230818 Understanding the mechanisms of clonal and non-clonal cytopenia following CAR-T therapy (MC230818)

    Albert Lea, MN, Scottsdale/Phoenix, AZ, Eau Claire, WI, Jacksonville, FL, La Crosse, WI, Mankato, MN, Rochester, MN

  7. A Study of CA-4948 in Patients With Relapsed or Refractory Primary Central Nervous System Lymphoma

    Scottsdale/Phoenix, AZ, Jacksonville, FL, Rochester, MN

  8. IDE196 (Darovasertib) in Combination With Crizotinib as First-line Therapy in Metastatic Uveal Melanoma

    Rochester, MN

  9. A Study of the Drugs Selumetinib vs. Carboplatin and Vincristine in Patients with Low-Grade Glioma

    Rochester, MN

  10. A Study Evaluating The Safety, Efficacy, And Pharmacokinetics Of Mosunetuzumab And A Combined Regimen Of Mosunetuzumab And Venetoclax In Participants With Relapsed Or Refractory Chronic Lymphocytic Leukemia

    Rochester, MN

.

Mayo Clinic Footer